

**RECEIVED
CENTRAL FAX CENTER****DEC 01 2008**DOCKET: 203/505 US; MB-104
APPLICATION: 10/821,383IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn Re Application of:
Christopher H. PorterExaminer : Christopher Koharski
Art Unit: 3763

Applic.: 10/821,383

Filed: 04/09/2004

For: PERCUTANEOUSLY IMPLANTABLE
MEDICAL DEVICE CONFIGURED TO
PROMOTE TISSUE INGROWTHAmendment Responsive
to Office Action
dated 08/21/2008
(Reformatted Amendment)Commissioner for Patents
Alexandria, VA 22313-1450REMARKS

The Office Action dated 08/21/2008 has been carefully considered. It is noted that the prior final rejection has been withdrawn "in view of new prior art", that claims 1, 3 16 and 18-21 are currently pending, and that claims 10-12 have been withdrawn. It is further noted that claims 1, 3-9, 13-16, and 18-21 have been rejected under 35 U.S.C. 103 as being unpatentable over (1) Poirier (US 4,668,222) in view of de Groot (EP 0367354) and (2) Thramann (US 5,360,448) in view of de Groot. As a consequence of the new grounds of rejection, independent claims 1 and 16 are being canceled in favor of newly drafted independent claims 22 and 23, respectively. The current claim amendments are set forth with particularity in the attached Claim Listing. Note that the cancellation of claim 9 obviates the objection to the Specification.

-1-

MRPB344.RESPONSE TO OA 505

12/1/2008 3:01 PM

DOCKET: 203/505 US; MB-104
APPLICATION: 10/821,383

1 The present invention is directed to a medical device 30 configured for implantation
2 in a patient's soft tissue, e.g., in a patient's retro-auricular space 28. As discussed on
3 page 4 of the Specification, it is intended to implant the device 30 in a recess 32 by
4 surgically tunneling through space 28. Accordingly, the device 30 in accordance with the
5 invention is configured with a lateral profile particularly suited to be longitudinally advanced
6 through a surgically formed tunnel.
7

8 The device 30 is comprised of a housing body 42 having a lateral shoulder 60 and a
9 stud 62 extending longitudinally from the shoulder. The longitudinal peripheral surface of
10 the stud carries a longitudinal porous layer 30 for promoting soft tissue ingrowth.
11 Additionally, the lateral surface of shoulder 60 carries a lateral porous layer which extends
12 orthogonal to and abuts the longitudinal porous layer. The orthogonal porous layers
13 function together to promote soft tissue ingrowth, promote vascularization and form an
14 infection resistant barrier while also providing enhanced anchoring.
15

16 To enable the device 30 to be implanted by surgical tunneling, the housing body 42
17 defines a substantially uniform lateral dimension (see, e.g., Figures 5, 7, 12, 13A-C) and
18 the lateral and longitudinal porous layers define lateral dimensions equal to or less than
19 the housing body lateral dimension. This structural configuration allows the device 30 to
20 be longitudinally advanced through a small surgically formed tunnel to subcutaneously
21 implant the housing body 42 and percutaneously implant the projecting stud 62.
22

23 The Office Action initially rejects independent claims 1 and 16 (now cancelled in
24 favor of new claims 22 and 23) under 35 USC 103 as unpatentable over newly cited
25 Poirier in view of de Groot. Both of these references show percutaneously implantable
26 access devices each having a flange or skirt carrying porous material useful for
27 subcutaneous anchoring. In each case, the flange extends laterally beyond the lateral
28

-2-

MRPB344.RESPONSE TO OA 505

12/1/2008 3:01 PM

DOCKET: 203/505 US; MB-104
APPLICATION: 10/821,383

1 dimension of the device body. Thus, neither of these references suggest a device
2 construction suitable for implantation via surgical tunneling as contemplated by the present
3 invention.

4 More particularly, note that Poirier describes multiple embodiments each including a
5 flange or flat skirt, e.g., 22, 62, for subdermal anchoring. Further note that the Poirier
6 flange has a lateral dimension, or diameter which is considerably larger than the lateral
7 dimension of his device body. As a consequence, Poirier fails to suggest a device suited
8 for implantation by surgical tunnelling. Rather, the Poirier device requires a relatively large
9 surgical incision to allow the device flange to be inserted therethrough for subcutaneous
10 implantation. The requirement to form a large incision, as contrasted with surgical
11 tunneling, results in greater patient tissue damage, increased patient discomfort, and
12 longer healing time.
13

14 The de Groot reference also teaches the use of a subdermal flange 2 for anchoring.
15 As is apparent from de Groot's disclosure, his flange 2 has a much larger lateral dimension
16 than the de Groot implant 10. Accordingly de Groot fails to suggest a device construction
17 suited for implantation by longitudinally advancing the device through a surgically formed
18 tunnel.
19

20 Applicant's new independent apparatus claim 22 has been carefully drafted to recite
21 the distinguishing characteristics of embodiments of the invention which render them
22 suitable for implantation by surgical tunneling and which afford the benefits identified in
23 Applicant's Specification, i.e., promoting soft tissue ingrowth and vascularization, and
24 forming an infection resistant barrier. Thus, claim 22 recites that the housing body has a
25 substantially uniform lateral dimension and that the longitudinally and laterally extending
26 porous layers abut one another and have lateral dimensions which are no greater than the
27
28

-3-

MRPB344.RESPONSE TO OA 505

12/1/2008 3:01 PM

DOCKET: 203/505 IJS; MR-104
APPLICATION: 10/821,383

1 housing body lateral dimension. These limitations structurally distinguish claim 22 over the
2 Poirier and de Groot teachings and afford significant functional advantages over the cited
3 prior art. Accordingly, favorable consideration is respectfully requested.

4 Applicant's new independent method claim 23 has been similarly drafted to define a
5 method of "configuring a medical device for implantation by surgical tunneling". Claim 23
6 recites providing a housing body defining a "substantially uniform lateral dimension" and
7 forming a longitudinal porous layer "having a lateral dimension no greater than said
8 housing body lateral dimension" and forming a lateral porous layer "having a lateral
9 dimension no greater than said housing body lateral dimension". Further, claim 23 recites
10 that the lateral porous layer is positioned to abut the longitudinal porous layer. It is
11 accordingly urged that claim 23 thus patentably distinguishes over the Poirier and de Groot
12 teachings and favorable consideration is requested.

13
14 The Office Action also rejects independent claims 1 and 16 (now canceled in favor
15 of new claims 22 and 23) under 35 USC 103 as unpatentable over newly cited Thramann
16 view of de Groot. Thramann discloses a bone screw having a shaft including
17 "longitudinally extending regions, one or more of which have bone ingrowth porous
18 surfaces and alternate with regions having threaded surfaces."

19
20 The Office Action recognizes that Thramann fails to teach Applicant's pore size and
21 porosity limitations (recited in claims 22 and 23) but contends that "it would have been
22 obvious to use the porous materials of de Groot with the system of Thramann ". With due
23 respect to the examiner's contention, it is nevertheless urged that the proposed
24 combination of references is not well taken. Thramann is solely concerned with long term
25 "fixation of the screw to the bone " whereas de Groot is concerned with anchoring in "soft
26 tissue", "when no boney tissue is present". The respective references address very
27
28

-4-

MRPB344.RESPONSE TO OA 505

12/1/2009 3:01 PM

DOCKET: 203/505 US; MB-104
APPLICATION: 10/821,383

1 different problems and propose distinct solutions. It appears that nothing, other than
2 perhaps Applicant's disclosure, would prompt a combination of the Thramann and de
3 Groot teachings. And, it is respectfully urged, that reliance on Applicant's disclosure
4 represents the application of impermissible hindsight reasoning. As noted in MPEP 2142,
5 "impermissible hindsight must be avoided and the legal conclusion must be reached on the
6 facts gleaned from the prior art".
7

8 In any event, assuming arguendo that the combination of Thramann and de Groot
9 was appropriate, nevertheless they fail to suggest the invention recited in claims 22 and
10 23. Note particularly that claim 22 recites orthogonal longitudinally and laterally extending
11 porous layers positioned to abut one another, as clearly depicted in Applicant's drawings
12 (e.g., Figures 5, 7, 8, 12). These limitations clearly structurally distinguish claim 22 over
13 the cited art and yield the benefits stressed in the specification of promoting soft tissue
14 ingrowth and vascularization, forming an infection resistant barrier, and providing
15 enhanced anchoring.
16

17 Method claim 23 similarly distinguishes over the cited art by reciting that the lateral
18 porous surface is positioned to orthogonally abut the longitudinal porous surface.
19

///

///

///

///

///

///

///

DOCKET: 203565 US; MB-104
APPLICATION: 10/821,388

1 In view of the foregoing, it is urged that independent claims 22 and 23 patentably
2 distinguish the present invention over the cited prior art and favorable consideration of
3 these claims, along with remaining dependent claims 3-8 and 18-21, is courteously
4 requested.
5
6

7 Respectfully submitted,



8
9
10 ARTHUR FREILICH
11 Reg. No. 19, 281
12 Attorney for Applicant(s)
13 FREILICH, HORNBAKER & ROSEN
14 20555 Devonshire St. #372
15 Chatsworth, CA 91311
16 TEL. 818-678-6408 • FAX 818-678-6411

DEPOSIT ACCOUNT AUTHORIZATION:


16 Throughout the prosecution of this application the Patent and
17 Trademark Office is authorized to charge any additional fees which may
18 be required, or credit any overpayment to Account No. 501232.



ARTHUR FREILICH, Reg. No. 19,281

CERTIFICATION OF MAILING:

19 I hereby certify that this correspondence is being deposited with the United
20 States Postal Service with sufficient postage as first class mail in an envelope
21 addressed to: Commissioner for Patents, Alexandria, VA 22313-1450, or
22 being facsimile transmitted to the USPTO (571) 273-8300,
23 on Dec 1, 2008.



ARTHUR FREILICH